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Abstract
Background: Prior studies have described a reduced risk of developing ovarian cancer with the use of oral
contraceptives. In this context, we decided to examine if oral contraceptive use prior to a diagnosis of ovarian
cancer is associated with better overall and progression-free survival.
Methods: This retrospective cohort study included ovarian cancer patients who were seen at the Mayo Clinic in
Rochester, Minnesota from 2000 through 2013. Patients completed a risk factor questionnaire about previous oral
contraceptive use, and clinical data were extracted from the electronic medical record.
Results: A total of 1398 ovarian cancer patients responded to questions on oral contraceptive use; 571 reported no
prior use with all others having responded affirmatively to oral contraceptive use. Univariate analyses found that
oral contraceptive use (for example, ever versus never) was associated with better overall survival (hazard ratio (HR)
0.73 (95 % confidence interval (CI): 0.62, 0.86); p = 0.0002) and better progression-free survival (HR 0.71 (95 % CI:
0.61, 0.83); p < 0.0001). In multivariate analyses, contraceptive use continued to yield a favorable, statistically
significant association with progression-free survival, but such was not the case with overall survival.
Conclusions: This study suggests that previous oral contraceptive use is associated with improved progression-free
survival in patients diagnosed with ovarian cancer.
Keywords: Ovarian cancer, Survival, Oral contraceptives
Decades of data show that oral contraceptive use re-
duces the risk of ovarian cancer. A greater than 20 %
relative risk reduction appears to occur for every 5 years
a woman reports taking oral contraceptives [1]. This risk
reduction is particularly salient among women who have
used oral contraceptives for 10 years or longer at any
point in their lives, and it also occurs in high-risk
women, such as those with BRCA1 and BRCA2 germline
mutations [2]. Continuous ovulation is thought to pre-
dispose to ovarian epithelial cell DNA damage, which in
turn gives rise to carcinogenesis, thus providing mechan-
istic plausibility to how cessation of ovulation from oral
contraceptives might lead to lower cancer risk [3].
Although large pooled analyses suggest that oral contra-
ceptives could prevent 200,000 cases of ovarian cancer
and 100,000 deaths from this malignancy over 20 years,
such deductions have not spawned large-scale preven-
tion trials [4, 5]. The many decades of follow up required
to capture a small number of cancer cases, the enor-
mous funding necessary to conduct prevention trials of
sizable complexity, and the fact that oral contraceptives
can also confer negative effects, such as an increased risk
of thrombophlebitis and breast cancer, all lessen enthusi-
asm for the conduct of such prevention trials. Moreover,
to date, the above robust observation has not yet dra-
matically changed clinical practice.
In contrast to these data on ovarian cancer prevention,
few studies have specifically sought to assess whether
oral contraceptives prior to an ovarian cancer diagnosis
is associated with better outcomes after contracting this
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malignancy. This possibility builds on previous data on
the purported role of oral contraceptives in preventing
ovarian cancer. Moreover, in contrast to primary preven-
tion, establishing this observation could lead to pro-
spective research aimed at improving outcomes in
ovarian cancer patients. Thus, to further examine the
effects of previous oral contraceptives on outcomes in
ovarian cancer patients, we studied patients at the Mayo
Clinic in Rochester, Minnesota. Our main aim was to
determine whether oral contraceptive use prior to a
diagnosis of ovarian cancer is associated with better
overall and progression-free survival within the context
of in depth multivariate analyses undertaken within a




This study focused on women with invasive primary epi-
thelial ovarian, fallopian tube, or peritoneal cancer seen
at the Mayo Clinic in Rochester, Minnesota. The study
of all these tumors in aggregate has substantial prece-
dent because these malignancies behave and are treated
similarly. The Mayo Clinic Institutional Review Board
(IRB) approved this study. As described previously,
patients were consecutively recruited from 2000 through
2013 from the Mayo Clinic in Rochester, Minnesota [6].
All patients had to be 20 years of age or older and had
to have provided written informed consent. Patients
then completed a paper risk factor questionnaire (see
below) that included queries on previous oral contracep-
tive use. Trained medical personnel extracted details on
tumor histology, type of surgery, and administration of
chemotherapy from the electronic medical record.
Study endpoints
Outcome data were acquired through April 2014. Data
on cancer recurrence were updated via the Mayo Clinic
electronic medical record and included a mailed ques-
tionnaire to patients and medical record review. Vital
status was gleaned from the Mayo Clinic electronic
medical record, the Mayo Clinic Cancer Registry, and
registration records. Death certificates were requested
from the appropriate government bodies with the appro-
priate permissions to confirm dates of death.
This study analyzed overall survival, as defined as the
interval from a histologic-or cytologic-confirmed cancer
diagnosis to date of death. If vital status was unknown
for a specific patient, that patient was censored on the
date of last contact or at five years, whichever occurred
first. The rationale for this approach rests in the fact that
the majority of ovarian cancer-related deaths occur in
the first five years after diagnosis. Progression-free sur-
vival was also assessed and was defined as the date from
cancer diagnosis to the date of initiation of second-line
cancer treatment or death. Although vital status was
assessed in all patients, progression-free survival had
been assessed in only a subset.
Definition of covariates
Oral contraceptive use was the main variable of interest,
and it was assessed by means of a self-administered
questionnaire. Patients were asked, “Have you ever used
oral contraceptive pills (“the pill”)?” and were asked to
mark the appropriate response of “yes” or “no.” If they
answered “yes,” they were then asked to estimate dur-
ation of use in years, as summarized in this report as
both a categorical variable (1–48 months and > 48
months) and a continuous variable. Other hormone-
related variables were also assessed; these included age
at menarche and menopause status. Patients were also
assessed for number of live births, coded as nulliparous
versus one or two versus three or more. This grouping
of parity was done because of efforts to maintain statis-
tical power and because it appeared clinically reasonable.
A variety of clinical covariates, many of which have
prognostic associations, were also considered. These
consisted of 1) cancer stage; 2) cancer histology: high
grade serous, low grade serous, endometrioid versus
clear cell, mucinous, mixed epithelial, borderline invasive
mixed epithelial, and other; 3) tumor grade; 4) outcome
of initial surgery: no residual disease versus </= 1 cm of
residual disease versus > 1 cm residual disease; 5)
platinum-based chemotherapy administered within the
first three months of surgery: yes versus no [7]; 6) pa-
tient age at cancer diagnosis; 7) smoking history: never
versus former versus current; and 8) first degree family
history of breast or ovarian cancer: yes versus no.
Analyses
Chi-square or Wilcoxon rank-sum tests were used, as
appropriate, to compare all the covariates between
never- and ever- oral contraceptive users. Univariate
analyses were undertaken for all the variables described
above. Oral contraceptive use was examined in two sep-
arate analyses: 1) based on a “ever” and “never” patient
response and 2) based on duration of oral contraceptive
use: never versus 1–48 months versus > 48 months or
patient-reported years of use as a continuous variable.
All variables were examined to assess their individual
associations with overall survival and progression-free
survival. Kaplan Meier curves were constructed to
visualize unadjusted associations. Cox proportional haz-
ards modeling accounting for left truncation was used
for univariate and multivariate analyses with estimation
of HRs and 95 % CIs. Left truncation is a standard
method undertaken to limit sampling bias when one is
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Table 1 Demographics
Characteristic Oral contraceptive usea P-valueb
Never-Used Ever-Used Total
n = 571 n = 827 n = 1398
(%) (%) (%)
Age at diagnosis, median in years (range) 69 (24, 93) 58 (21, 91) 61 (21, 93) <0.0001
Cancer stage
1 77 (14) 149 (19) 226 (17) 0.07
2 34 (6) 44 (6) 78 (6)
3 322 (60) 460 (59) 782 (60)
4 106 (20) 124 (16) 230 (17)
Tumor Type
High-grade serous 320 (56) 419 (51) 739 (53) 0.09
Endometrioid 71 (12) 91 (11) 162 (12)
Clear cell 32 (6) 46 (6) 78 (6)
Mucinous 9 (2) 23 (3) 32 (2)
Other 139 (24) 147 (29) 387 (27)
Grade
1 22 (5) 49 (8) 71 (7) 0.06
2 45 (10) 77 (12) 122 (11)
3 260 (58) 362 (58) 622 (58)
4 123 (27) 140 (22) 263 (24)
Tumor Debulking Status
No residual disease 218 (39) 393 (48) 611 (45) 0.004
Less than or equal to 1 centimeter 150 (27) 172 (21) 322 (24)
Optimal but amount of residual disease unknown 79 (14) 105 (13) 184 (13)
Suboptimal 79 (14) 86 (11) 165 (12)
Unknown 33 (6) 57 (7) 90 (7)
Platinum-based chemotherapy within 3 months of surgery
Yes 309 (87) 530 (93) 839 (90) 0.002
No 48 (13) 42 (7) 90 (10)
Age at menarche, median in years (range) 13 (9, 19) 13 (8, 19) 13 (8, 19) 0.19
Age at menopause, median in years (range) 50 (18, 76) 50 (21, 60) 50 (18, 76) 0.26
Number of live births
0 113 (20) 139 (17) 252 (18) <0.0001
1-2 177 (31) 374 (45) 551 (40)
3 or more 278 (49) 313 (38) 591 (42)
Smoking
Never 342 (66) 480 (62) 822 (64) 0.25
Former 136 (26) 234 (30) 370 (29)
current 38 (7) 63 (8) 101 (8)
Breast or ovarian cancer in a first-degree relative
Yes 133 (24) 188 (23) 321 (23) 0.75
No 426 (76) 628 (77) 1054 (77)
aNumbers may not sum to the whole cohort or to 100 % either because of missing values or rounding, and numbers in parentheses represent percentages unless
otherwise specified
bChi square or Wilcoxon rank-sum test were used to compare Never- and Ever-Users, as appropriate
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unable to consistently observe the time when an event
might have occurred.
Multivariate analyses were then conducted to identify
the independent prognostic association of each of these
variables and to estimate the effects of these variables on
overall and progression-free survival endpoints. Three
models were constructed with inclusion of 1) all vari-
ables except those with high rates of missing data; 2)
variables that, in univariate analyses, had yielded a statis-
tically significant association (p < 0.01) with overall and
disease-free survival; and 3) variables that, in univariate
analyses, had yielded a statistically significant association
with overall survival and disease-free survival (p < 0.01)
except those with notable missing data. These models
were constructed in this manner to avoid biases that
might arise from missing data. All statistical tests were
two-tailed, and a p-value of < 0.05 is considered statisti-
cally significant. All statistical analyses were performed
using Statistical Analysis Software version 9.3 (SAS
Institute, Cary, North Carolina).
Results
Demographics
This study focused on 1398 ovarian cancer patients who
had completed a questionnaire on oral contraceptive use
at study entry. Within this cohort, 571 reported no prior
oral contraceptive use. Among oral contraceptive users,
the patient-reported median duration was 60 months
(range: 1 to 444 months).
Baseline characteristics appear in Table 1. Patients
who had used oral contraceptives were more likely to
have had no residual disease from surgery but were less
likely to have started platinum-based chemotherapy after
surgery. Patients who had used oral contraceptives were
also diagnosed at an earlier age and had fewer live births.
Overall survival and progression-free
At the time of this report, 562 patients had died, and
656 had developed recurrent cancer or had died after ac-
counting for left truncation. Univariate analyses, which
do not take into account confounding factors, suggested
that oral contraceptive use (ever versus never) was asso-
ciated with better overall survival (HR 0.73 (95 % CI:
0.62, 0.86); p = 0.0002) (Fig. 1). Similarly, univariate ana-
lyses also suggest oral contraceptives (ever versus never)
was associated with more favorable progression-free sur-
vival (hazard ratio (HR) 0.71 (95 % confidence interval
(CI): 0.61, 0.83); p < 0.0001) (Fig. 2). These survival ad-
vantages were also observed when oral contraceptive use
was further characterized based on duration of use.
Compared to never users, patients who reported using
oral contraceptive for one to 48 months manifested a
more favorable overall survival and progression-free sur-
vival, as did patients who reported using them for more
than 48 months (data not shown).
In the three constructed multivariate models, oral
contraceptive use did not yield a statistically significant
improvement in overall survival, but it did yield such an
association with improved progression-free survival
(Table 2).
Of note, the multivariate models pointed to patient
age as a major confounder, as younger age was strongly
associated with oral contraceptive use. For example, in
the first model, with no adjustment for age, oral contra-
ceptive use was, in fact, associated with better overall
survival (HR = 0.70; p < 0.001) as well as with better
Fig. 1 Overall Survival Based on Ever- (solid line) and Never-Users (dashed line) of Oral Contraceptives. In univariate analyses ever-users of oral
contraceptives (n = 793) manifested a longer overall survival compared to never-users (dashed line) (n = 551) (HR = 0.73 (95 % CI: 0.62,
0.86); p = 0.0002 (accounting for left truncation). Within the cohort were a total of 562 deaths. Similar statistically significant findings were
seen in univariate analyses when patients were dichotomized on the basis of duration of oral contraceptive use
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progression–free survival. However, after adjusting for
age, this association with overall survival lost its statistical
significance, although the association with improved
progression-free survival was maintained. Furthermore,
we performed separate analyses on associations with oral
contraceptive use and overall survival and progression-
free survival based on whether patients had residual
disease postoperatively and found these prognostic associ-
ations with oral contraceptive use were sustained.
Discussion
This study examined whether oral contraceptive use
prior to a diagnosis of ovarian cancer was associated
with improved overall survival and progression-free sur-
vival. We observed this protective association in univari-
ate analyses, but multivariate analyses yielded less
consistent findings. In the latter, prior oral contraceptive
use was associated with improved progression-free
survival but not with overall survival. Younger patients
reported greater use of oral contraceptives as well as
longer survival. This study provides corroborative evi-
dence that previous oral contraceptive use is associated
with better clinical outcomes in patients diagnosed with
ovarian cancer, at least with respect to progression-free
survival.
Indeed, our findings are particularly noteworthy
because of the detailed nature of our multivariate
analyses. The fact that we were able to adjust for highly
relevant clinical co-variates such as the extent of the pri-
mary debulking surgery and the fact that we had detailed
follow up information on consecutively-treated patients
strengthen this report. Our study provides an important
contribution to an emerging body of literature that
indicates oral contraceptive use prior to a diagnosis of
ovarian cancer is associated with better outcomes. Only
a few studies have examined whether oral contraceptives
appear to change outcomes in patients who develop
ovarian cancer at a later date. First, using the Nurses’
Health Study, the New England Case–control Study, the
Australian Ovarian Cancer Study, and the NIH-AARP
Diet and Health Study, Poole and others examined
numerous lifestyle factors and their effect on clinical
outcomes in ovarian cancer patients [5]. Among 4,342
patients with ovarian cancer, previous oral contraceptive
use was associated with a lower risk of death (five-year
increase in relative risk 0.69 (95 % confidence interval
(CI): 0.58, 0.82)). These investigators noted that their
study design might not have captured patients with rap-
idly fatal malignancies and that limited clinical data were
available to accommodate some of their analyses. None-
theless, this observation appears plausible, particularly
given the earlier-referenced studies that have focused on
cancer prevention. Second, several investigators, includ-
ing Vessey and others from the Oxford Family Planning
Association Contraceptive Study, Hannaford and others
from the Royal College of General Practitioners’ Oral
Contraceptive study, and those from the Collaborative
Group on Epidemiological Studies of Ovarian Cancer
have also reported decreased overall mortality among
ovarian cancer patients who had used oral contracep-
tives prior to their cancer diagnosis [1, 8, 9]. The above
two studies used a cohort design of oral contraceptive
users and non-users and reported on death from ovarian
cancer. These studies confirm the observation from
Poole and others, although their primary goal was to
understand cancer risk.
Fig. 2 Progression-Free Survival Based on Ever- (solid line) and Never-Users (dashed line) of Oral Contraceptives. In univariate analyses ever-users
of oral contraceptives (n = 700) manifested a longer progression-free survival compared to never-users (dashed line) (n = 489) (HR = 0.71 (95 %
CI: 0.61, 0.83); p < 0.0001 (accounting for left truncation). Within the cohort were a total of 656 events of cancer progression. Similar statistically
significant findings were seen in univariate analyses when patients were dichotomized on the basis of duration of oral contraceptive use
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However, not all studies of oral contraceptive use and
outcome have been consistent. For example, Nagle and
others reported on 676 women diagnosed with ovarian
cancer, and, although 310 women had used oral contra-
ceptives, the latter did not demonstrate a protective
association with respect to ovarian cancer mortality
(adjusted hazard ratio (HR) 0.88 (95 % CI: 0.70, 1.11)
[10]. This study examined a cohort of women with
ovarian cancer and looked at survival of cancer patients
who were users of oral contraceptives and cancer
patients who were not users of oral contraceptives.
These authors concluded that “reproductive and
hormonal exposures prior to diagnosis do not influence
survival from invasive ovarian cancer, in contrast to
their substantial effects on the etiology of this disease,”
and others have drawn similar conclusions [11]. Taken
together, these studies provide justification for generating
the study reported here.
Is this favorable association between prior oral contra-
ceptive use and survival mechanistically plausible? It ap-
pears to be. First, as alluded to earlier, previous studies
that have shown oral contraceptives protect against the
development of primary ovarian cancer suggest that ces-
sation of ovulation halts the repeated monthly trauma
that occurs on the surface of the ovary, thereby limiting
the possibility of epithelial cell mutation and subsequent
carcinogenesis [3]. Similar mechanisms might be in-
voked to explain the favorable prognostic associations
observed here. In an analogous fashion, epithelial ovar-
ian cancer cells that undergo repeated, monthly trauma
from ovulation are perhaps more likely to develop DNA
mutations. The more frequent the trauma, the more apt
these cells are to develop aberrant DNA mutations; the
more numerous the DNA mutations, the more aggres-
sive the cancer [12]. Although this line of thinking may
contradict the hypothesis that ovarian cancer originates







(95 % CI) for
overall survival
P-Value N (events) for
progression-free
survival








857 (383) 0.91 (0.70, 1.19) 0.27 800 (467) 0.71 (0.56, 0.91) 0.03
>48 months vs
never
0.80 (0.61, 1.05) 0.83 (0.66, 1.06)
Duration of use as
a continuous
variable








926 (418) 1.01 (0.78, 1.30) 0.35 858 (506) 0.74 (0.59, 0.94) 0.04
>48 months vs
never
0.84 (0.65, 1.10) 0.86 (0.68, 1.08)
Duration of use as
a continuous
variable





Ever vs Never Users 1204 (511) 0.95 (0.78, 1.15) 0.57 1111 (619) 0.84 (0.70, 0.996) 0.046
Duration of use 1173 (497) 0.80 1083 (601) 0.052
1–48 months vs
never
1.00 (0.79, 1.27) 0.77 (0.62, 0.95)
>48 months vs
never
0.93 (0.74, 1.18) 0.89 (0.72, 1.09)
Duration of use as
a continuous
variable
1173 (497) 0.999 (0.997, 1.001) 0.19 1083 (601) 0.999 (0.998, 1.000) 0.15
aAdjusted for all variables from Table 1 except for age at menarche, age at menopause, and platinum-based chemotherapy within 3 months, all of which were
missing in approximately 450 patients
bStatistically significant variables in univariate analyses include tumor stage, tumor type, tumor grade, debulking status after surgery, age at cancer diagnosis, and
number of live births
cTumor grade was excluded because it was missing in approximately 300 patients
NOTE: When age was excluded, all the oral contraceptive use models reached statistical significance (p < 0.05), except in the progression-free survival model that
used continuous duration of oral contraceptive use as the key variable
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from fallopian tube fimbria, it nonetheless merits con-
sideration, particularly because the fimbria are also
exposed to hormones in the follicular fluid [13]. Second,
in a preclinical model, Romero and others observed that
contraceptive hormone exposure decreased matrix
metalloproteinase-2 activity, invoking this observation to
explain the effects of oral contraceptives on carcinogen-
esis and perhaps also on the improved clinical outcomes
observed by us and others [14]. One might speculate
that the role of matrix metalloproteinase-2 proteins in
modifying the extracellular matrix confers long-term
consequences that attenuate the malignant potential of
ovarian cancers and provide greater susceptibility to cancer
treatment. In view of a growing literature that underscores
an inverse association between oral contraceptive use and
poor outcomes from ovarian cancer, it appears important
to probe into and delineate the mechanisms that underlie
these observations, such as those posited above.
Our study has at least three limitations. First, the
questionnaire we used did not capture detailed infor-
mation on oral contraceptive product formulation,
which may be informative, as oral contraceptives with
high progesterone content appear to carry a more
protective effect [15]. Second, the exact cause of
death for many patients is still being curated and thus
cause-specific mortality was not analyzed here, although
our use of censoring data at date of last contact and limit-
ing follow up to 5 years post-diagnosis are attempts to
mitigate this limitation. Nonetheless, it remains possible
that deceased older patients had died more frequently of
non-cancer causes, a plausible scenario that might explain
why our study did not reveal an improvement in overall
survival with oral contraceptive use in multivariate ana-
lyses, despite having captured an improvement in
progression-free survival. Finally, this study provides lim-
ited data on how recently oral contraceptives had been
used, and such timing issues would likely have an import-
ant impact on the strength of this association. Despite
such limitations, our study – coupled with several that
preceded it – points to a need to investigate mechanisms
that explain how and why prior oral contraceptive use ap-
pears to improve clinical outcomes in ovarian cancer pa-
tients. Understanding such mechanisms might lead to
more effective therapeutic interventions in patients
diagnosed with this malignancy.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
AJ, NF, KK, RV, ZZ, ML, BF, and EG contributed to the conception, design,
analysis, and interpretation of data. AJ, NF, KK, RV, ZZ, ML, BF, and EG were
all involved in drafting the manuscript or revising it critically for important
intellectual content. All authors have given final approval of the version to
be published. All agree to be accountable for all aspects of this work.
Acknowledgement
The authors acknowledge Karin Goodman, APRN, CNP for her work in
abstracting the data from the clinical records for this study.
This work was supported in part by P50CA136393, P30CA15083, and
R01CA122443 from the United States’ National Cancer Institute.
Author details
1Department of Oncology, Mayo Clinic, 200 First Street SW, Rochester, MN
55905, USA. 2Department of Health Sciences Research, Mayo Clinic,
Rochester, MN, USA. 3Department of Kinesiology and Community Health,
University of Illinois at Urbana-Champaign, Champaign, IL, USA. 4Department
of Biostatistics, University of Kansas Medical Center, Kansas City, KS, USA.
Received: 26 February 2015 Accepted: 10 October 2015
References
1. Collaborative Group on Epidemiological Studies of Ovarian Cancer, Beral V,
Doll R, Hermon C, Peto R, Reeves G. Ovarian cancer and oral contraceptives:
collaborative reanalysis of data from 45 epidemiological studies including
23, 257 women with ovarian cancer and 87,303 controls. Lancet.
2008;371(9609):303–14.
2. Friebel TM, Domcheck SM, Rebbeck TR. Modifiers of cancer risk in BRCA1
and BRCA2 mutation carriers: systemic review and meta-analysis. J Nat
Cancer Inst. 2014;106:1093.
3. Wong AS, Leung PC. Role of endocrine and growth factors on the ovarian
surface epithelium. J Obstet Gyneacol Res. 2007;33:3–16.
4. Bosetti C, Negri E, Trichopoulos D, Franceschi S, Beral V, Tzonou A, et al.
Long-term effects of oral contraceptives on ovarian cancer risk. Int J Cancer.
2002;102:262–5.
5. Poole EM, Merritt MA, Jordan SJ, Yang HP, Hankinson SE, Park Y, et al.
Hormonal and reproductive risk factors for epithelial ovarian cancer by
tumor aggressiveness. Cancer Epidemiol Biomarkers Prev. 2013;22:429–37.
6. Peethambaram P, Fridley BL, Vierkant RA, et al. Polymorphisms in ABCB1
and ERCC2 associated with ovarian cancer outcome. Int J Mol Epidemiol
Genet. 2011;2:185–95.
7. Hofstetter G, Concin N, Braicu I, Chekerov R, Sehouli J, Cadron I, et al. The time
interval from surgery to start of chemotherapy significantly impacts prognosis
in patients with advanced serous ovarian carcinoma – analysis of patient data
in the prospective OVCAD study. Gynecol Oncol. 2013;131:15–20.
8. Vessey M, Yeates D. Oral contraceptive use and cancer: final report from the
Oxford-Family Planning Association contraceptive study. Contraception.
2013;88:678–83.
9. Hannaford PC, Selvaraj S, Elliott AM, Angus V, Iversen L, Lee AJ. Cancer risk
among users of oral contraceptives: cohort data from the Royal College of
General Practitioner’s oral contraceptive study. BMJ. 2010;340(340):927.
10. Nagle CM, Bain CJ, Green AC, Webb PM. The influence of reproductive and
hormonal factors on ovarian cancer survival. Int J Gynecol Cancer.
2008;18:407–13.
11. Yang L, Klint A, Lambe M, Bellocco R, Riman T, Bergfeldt K, et al. Predictors
of ovarian cancer survival: a population-based prospective study in
Sweden. Int J Cancer. 2008;123:672–9.
12. Giam M, Rancati G. Aneuploidy and chromosomal instability in cancer: a
jackpot to chaos. Cell Div. 2015;20.
13. Emori MM, Drapkin R. The hormonal composition of follicular fluid and its
implications for ovarian cancer pathogenesis. Reprod Biol Endocrinol.
2014;12:60.
14. Romero IL, Gordon IO, Jagadeeswaran S, Mui KL, Lee WS, Dinulescu DM,
et al. Effects of oral contraceptives or gonadotropic-releasing hormone
agonist on ovarian carcinogenesis in genetically engineered mice. Cancer
Prev Res. 2009;2:792–9.
15. Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC.
Impact of progestin and estrogen potency in oral contraceptives on ovarian
cancer risk. J Natl Cancer Inst. 2002;94:32–8.
Jatoi et al. BMC Cancer  (2015) 15:711 Page 7 of 7
